Kinaxo Starts Collaboration with Roche in the Field of Phosphoproteomics

23-Oct-2009 - Germany

Kinaxo Biotechnologies GmbH announced that it has entered into a collaboration with Roche Diagnostics GmbH. Under the agreement KINAXO's phosphoproteomics technology PhosphoScout® will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement were not disclosed.

Dr. Klaus Godl, KINAXO’s CSO commented: “We are very pleased to partner with Roche, a world leading healthcare company. Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs.”

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous